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Abstract
To date, almost one and a half million cases of cancer are diagnosed every year in the US and nearly 560,000 Americans 
are expected to die of cancer in the current year, more than 1,500 people a day (data from the American Cancer Society 
at http://www.cancer.org/). According to the World Health Organization (WHO), roughly 20% of all cancers worldwide 
results from chronic infections; in particular, up to 15% of human cancers is characterized by a viral aetiology with 
higher incidence in Developing Countries. The link between viruses and cancer was one of the pivotal discoveries in 
cancer research during the past Century. Indeed, the infectious nature of specific tumors has important implications in 
terms of their prevention, diagnosis, and therapy. In the 21st Century, the research on viral oncology field continues to 
be vigorous, with new significant and original studies on viral oncogenesis and translational research from basic 
virology to treatment of cancer. This review will cover different viral oncology aspects, starting from the history of viral 
oncology and moving to the peculiar features of oncogenic RNA and DNA viruses, with a special focus on human 
pathogens.
A brief history of viral oncology
The first evidence of tumor viral aetiology dates back to
1907 when Ciuffo and co-workers showed that human
warts could be transmitted by cell-free filtrates derived
from lesions [1]. Seventy years later, papillomaviruses
were linked to human cancer. In 1908, Ellermann and
Bang, reported that also leukemia could be transferred to
healthy chicken by a cell-free filtrate of cells obtained
form affected birds [2]. Moreover, in 1911, Rous and col-
leagues showed that the spindle cell sarcoma could be
transmitted to healthy chickens using filtered cell-free
tumor extracts [3]. This study led to the identification of
the first oncogenic virus: the Rous sarcoma virus (RSV).
Over the next four decades after the discovery of RSV
new tumor viruses were identified. In particular, in 1935,
Rous and Beard demonstrated that the cottontail rabbit
papillomavirus (CRPV), discovered few years earlier [2],
was able to induce skin carcinomas in domestic cottontail
rabbit [4]. Moreover, in 1951, studies by Gross and co-
workers led to the identification of the first mouse leuke-
mia virus (murine leukemia virus) [5], later confirmed by
Moloney and others [6-8], and in 1953 of a mouse virus
that induced a variety of solid tumors (mouse polyomavi-
rus) [9]. As far as primates is concerned, in 1962, Eddy,
Hilleman, and co-workers showed the tumorigenic
potential of simian virus 40 (SV40) [10,11] while, interest-
ingly, Trentin and colleagues reported, for the first time,
that viruses could be linked to cancer development also
in humans, at least under experimental conditions.
Indeed, these authors showed that specific human adeno-
viruses are tumorigenic in experimentally infected ani-
mals [12]. Starting from then, studies were focused on
connection among viruses and human cancer. In 1965,
E p s t e i n ,  B a r r ,  a n d  c o l l e a g u e s  w e r e  a b l e  t o  v i s u a l i z e  b y
electron microscopy herpesvirus-like particles in a cell
line, established from Burkitt's lymphoma (BL) [13]. This
virus resulted to be biologically and antigenically distinct
from other known human herpesviruses [14] and was
named Epstein-Barr Virus (EBV). In addition to a causal
role in BL, EBV infection has been subsequently associ-
ated with nasopharyngeal carcinoma, post-transplant
lymphomas, and some Hodgkin's lymphomas (HL), thus
representing the first known human tumor virus. In the
same year, Blumberg, during a study aimed to correlate
inherited polymorphic traits in different geographic areas
of the world with particular disease patterns, found that
one blood sample from an Australian aborigine contained
an antigen that reacted specifically with the serum from
an American haemophilia patient. This antigen was
named the Australia (Au) antigen and its role was
unknown till a technician working with human sera con-
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tracted hepatitis, becoming Au antigen-positive. In 1967
and 1968, Blumberg, Okochi, Murakami, and Prince,
published seminal studies showing that blood from hepa-
titis patients contained the Au antigen [15-17], being the
surface antigen of a hepadnavirus called hepatitis B virus
(HBV), the aetiologic agent of serum hepatitis disease
[18]. In 1975, Blumberg and colleagues linked chronic
HBV infection to hepatocellular carcinoma (HCC) [19],
which is among the most common cancers in the world.
Importantly, in 1976 the first effective HBV vaccine was
developed by large-scale purification of HBV surface
antigen from the serum of chronic HBV carriers [20] fol-
lowed by a second-generation recombinant HBV surface
antigen subunit vaccine produced in 1980 which is still in
use. The HBV vaccine protects not only from acute and
chronic hepatitis but also from the development of HCC
[21,22], thus representing a key achievement in cancer
research. The success of the HBV vaccine in decreasing
the incidence of liver cancer prompted similar efforts to
develop safe vaccines capable of preventing other types of
cancers. In particular, the attention was focused on cervi-
cal carcinoma. Indeed, in 1974, for the first time, Harald
zur Hausen had proposed that the human papillomavirus,
HPV, may represent the aetiologic agent for cervical can-
cer [23,24]. In particular, zur Hausen had demonstrated
the presence of novel types of HPV DNA, namely HPV16
and HPV18, in cervical cancers [25,26]. Evidence now
clearly indicates that different types of HPV are human
tumor viruses responsible for causing virtually all cases of
cervical cancer [27], the third leading cause of cancer-
related deaths in women worldwide. Furthermore, HPVs
have also being linked to other anogenital cancers, as well
as to a subset of head and neck cancers. In fact, HPVs are
associated with more human cancers than any other
virus, causing up to 500,000 cases of cancer per year
worldwide [28]. Consequently, HPV has emerged as one
of the most important risk factors for human cancer. In
2005 and 2006, large-scale clinical trials with a VLP-
based HPV vaccines have been undertaken [28] and cur-
rent estimates suggest that these HPV vaccines could pre-
vent more than 300,000 cervical cancer cases per year on
a global scale.
The most recent milestones in tumor virology have
come from the identification of additional human tumor
viruses: human T-cell leukemia virus type 1 (HTLV-1),
hepatitis C virus (HCV), Merkel cell polyomavirus
(MCPyV), and Kaposi's sarcoma virus (KSHV).
In 1980, Gallo and colleagues detected in cultured
human T-cell lymphoma cells retroviral reverse tran-
scriptase activity and visualized retroviral particles,
immunologically distinct from other known viruses [29].
The new retrovirus was named HTLV-1. In 1981, a causal
role for HTLV-1 in adult T-cell leukemia (ATL) was given
by the discovery of retroviral particles in cell lines derived
from patients [30]. Moreover, patients with ATL but not
control individuals were shown to produce antibodies
that specifically recognized antigens expressed in HTLV-
1-infected human T-cells. Since then different molecular
mechanisms behind HTLV-1 oncogenic activity have
been undisclosed and will be analysed later on in this
review.
In 1989, Houghton and colleagues, by employing an
innovative techniques based on phage display library,
identified an antigen encoded by a previously unknown
RNA virus, which was named HCV [31]. Moreover, using
the first serologic test for HCV, Houghton was also capa-
ble to confirm that HCV was indeed the aetiologic agent
for post-transfusion hepatitis related neither with HBV
nor with hepatitis A virus, an other hepatitis virus trans-
mitted by the fecal-oral route, via contaminated food or
drinking water [32,33]. In addition, he reported an associ-
ation between chronic HCV infection with HCC, similar
to the one well established for HBV [34,35].
Kaposi's sarcoma (KS) is an endemic tumor of the Med-
iterranean basin and Africa [36] rarely life-threatening,
usually affecting elderly males, with skin localization. In
acquired immune deficiency syndrome (AIDS) patients,
however, KS displays frequent involvement of extra-cuta-
neous sites, typically lungs and gastrointestinal tract, with
severe complications. Moreover, since AIDS patients
exhibited a 20,000-fold higher risk for developing KS, an
infectious aetiology for the tumor was suggested. Having
epidemiologic and experimental evidence ruled out a role
for the human immunodeficiency virus 1 (HIV-1) in this
context, the studies were focused on the research of new
sexually transmitted infectious agents. As with the search
for HCV, a modern molecular biological approach played
a central role in the identification of KSHV. Indeed, in
1994, Chang, Moore, and colleagues reported the use of
representational difference analysis to identify in 90% of
KS tissues from AIDS patients DNA fragments distantly
homologous to the herpesvirus EBV [37]. This new virus
was called KSHV or human herpesvirus type 8 (HHV-8).
Studies carried on in the past 15 years strongly indicate a
causal role for KSHV in the development of KS [36], even
though the viral infection is clearly not sufficient to pro-
duce the disease and other cofactors have been hypothe-
sized.
Finally, a new polyomavirus, MCPyV, has been recently
detected in samples derived from patient affected by an
aggressive human skin cancer, the Merkel cell carcinoma
[38,39].
A summary of the human viruses clearly linked to can-
cer development is reported in Table 1.
The viral oncogenetic mechanisms: an introduction
Tumor viruses are classified in two general groups based
on whether an RNA or DNA genome is packaged into theBergonzini et al. Infectious Agents and Cancer 2010, 5:11
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infectious viral particle. Besides the difference in replica-
tion and life cycle, RNA and DNA viruses differ also in
their general mechanisms of inducing cellular transfor-
mation/immortalization, the first step to tumor develop-
ment. RNA tumor viruses, in particular animal
retroviruses, are usually characterized by the ability to
carry and/or alter important cellular growth-regulatory
genes, namely the oncogenes. The proteins encoded by
these cellular genes are not essential for viral replication
and are usually key player in cell cycle control. On the
other hand, DNA tumor viruses (like SV40, mouse polyo-
mavirus, adenovirus, and papillomavirus) cause cell
transformation by encoding proteins of exclusively viral
origin and essential for viral replication.
Oncogenic RNA viruses: the oncogene discovery
The RNA viruses associated with human cancer are
mainly included in Retroviridae and Flaviviridae families
(Figure 1).
Animal retroviruses have been characterized earlier,
starting from the RSV studies. Indeed, one of the major
breakthrough in understanding the molecular mecha-
nisms behind the ability of RNA viruses to cause cancer
came from the RSV field. In particular, the observation
that cellular transformation and viral replication by RSV
were dissociable properties [40] suggested that the virus
was encoding a cancer-causing gene, dispensable for viral
replication. In 1970, Duesberg and Vogt by comparing the
genomes of two closely related replication-competent
RSV variants, one of which could transform cells and the
other which could not [41] demonstrated that the trans-
formation-competent RSV variant exhibited at the level
of the 3'-end additional sequences accounting for a
genome 20% larger than the one of transformation-defec-
tive RSV variant. This cancer-causing gene (oncogene)
was named src according to the type of tumor caused by
RSV in chickens, the sarcoma. The established dispens-
ability of the src gene for RSV replication lead to the
hypothesis that oncogenes have a cellular origin and that
carcinogenic events activate cellular genes to promote
cancer. Thus, the reverse transcriptase-dependent life
cycle typical of most RNA oncogenic viruses, like RSV,
would allow the viral genome to capture a cellular onco-
gene. In 1976, Bishop and Varmus proved that this
hypothesis was correct [42]. Indeed, they were able to
obtain src specific probes, starting from transforming
RSV genome, and demonstrated its hybridization with
the DNA of normal chicken cells and with the DNA of
other avian species, even though with lower stringency.
This evolutionary conservation of src sequences provided
strong evidence that src was indeed a cellular gene
acquired by RSV from the chicken genome, rather than
being a viral gene. Moreover, this finding suggested that
the cellular gene, designated a proto-oncogene, must sus-
tain a mutation to cause cancer thus associating tumors
with mutagenic events. Supporting this view, it was then
demonstrated that ras oncogenes present in human blad-
der carcinoma cell lines, and rat mammary carcinomas
contained a mutation crucial for inducing cellular trans-
formation absent in ras proto-oncogene present in nor-
mal cells [43,44]. Viral oncogenes carry as well mutations
or are constitutively expressed with negative effects on
cell proliferation control. Indeed, to date, more than 70
cellular proto-oncogenes have been identified through
studies of oncogenic retroviruses, and nearly all of these
genes code for key cell signaling proteins involved in the
control of cellular proliferation and apoptosis [45]. The
ability to encode viral oncogenes is not the only mecha-
Table 1: Human viruses associated with cancer development.
Virus family Virus Human tumors Vaccine
Papillomaviridae HPV16/18 Cervical, Anogenital and 
Oesophageus tumors
√
Polyomaviridae JCV Brain and Colon tumors
SV40 Mesothelioma and Colon 
tumors
MCPyV Merkel cell carcinoma
Hepadnaviridae HBV Hepatocellular carcinoma √
Flaviviridae HCV Hepatocellular carcinoma
Herpesviridae EBV Nasopharingeal carcinoma, 
Burkitt's lymphoma, 
Hodgkin's lymphoma, B-cell 
lymphoproliferative diseases
HHV-8 Kaposis's sarcoma, Primary 
effusion lymphoma
Retroviridae HTLV-1 Adult T-cell leukemiaBergonzini et al. Infectious Agents and Cancer 2010, 5:11
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nism by which RNA viruses can cause cancer. It has been
demonstrated that retroviruses not carrying oncogenes in
their genome may influence expression/function of cellu-
lar oncogenes by insertional mutagenesis [45].
Among human retroviruses, the earliest oncogenic
virus identified was HTLV-1, associated with the ATL, an
aggressive clonal malignancy of mature CD4+ T lympho-
cytes that presents after a 20-40 years period of clinical
latency [46]. Interestingly, HTLV-1 still represents the
only known human retrovirus directly linked to a specific
human malignancy. Indeed, several epidemiological and
molecular evidence implicates HTLV-1 as the aetiologic
agent of ATL: i) the geographic distribution of ATL in dif-
f e r e n t  w o r l d  a r e a s,  f r o m  J a p a n  t o  C e n t r a l  A f r i c a n ,  t h e
Caribbean basin, Taiwan, and Papua New Guinea
matches that of HTLV-1 infections [47]; ii) when checked,
ATL patients always underwent HTLV-1 infection; iii)
leukemic cells cultured derived from ATL patients are
positive for HTLV-1; iv) HTLV-1 infection of normal
human T cells induced cellular transformation and
immortalization.
Interestingly, by contrast to mechanisms typical of ani-
mal retroviruses, HTLV-1 does not cause cancer by inser-
tional mutagenesis or by capturing and activating cellular
proto-oncogenes. Rather, the major oncogenic determi-
nant of HTLV-1 is the viral Tax gene that encodes a pro-
tein essential for viral replication [48]. In particular, it has
been demonstrated that Tax associates with centrosomes,
causing their fragmentation [49], and it is crucial for
transactivation/repression of viral and cellular gene
Figure 1 (A) Representative* list of cellular/viral protein interactions involved in RNA virus-related oncogenic transformation; (B) Schemat-
ic representation of Tax and HBZ roles in HTLV-1 mediated oncogenesis. Tax modulates the expression of many viral and cellular genes and it 
also promotes malignant transformation through disruption of different host-cell growth control pathways, resulting in aberrant cell division. More-
over, Tax adversely influences cellular homeostasis through a number of mechanisms, including the physical interaction with cell-cycle regulators and 
transcriptional activation of cell-cycle control genes, leading to uncontrolled cell division and proliferation. The basic leucine zipper protein (HBZ) is 
encoded by the complementary strand of the HTLV-1 genome, and it is expressed in all ATL cells, where it is capable of promoting cell proliferation 
and suppressing Tax-mediated transactivation. LTR: Long Terminal Repeat; NFκB: Nuclear Factor kappa-light-chain-enhancer of activated B cells; MHC-
I: Major Histocompatibility Complex Class-I; STAT-5: Signal Transducer and Activator of Transcription-5; hTERT: human Telomerase Reverse Tran-
scriptase. *Additional cellular/viral interactions involved in cell transformation and oncogenetic mechanisms have been described. This list is repre-
sentative, not exhaustive.
Virus Viral  oncoprotein Cellular  targets
HTLV-1
Core and non structural 
proteins 
Tax NFκB, Akt, PDZ protein p300/CBPp53
A)
B)
HCV
HBZ
p12 MHC-I, STAT-5
CREB-2
hTERT, p53, Rb
Tat HIV pRb2/p130Bergonzini et al. Infectious Agents and Cancer 2010, 5:11
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expression. Oncogenic transformation of infected and
transfected cells would hence be due to the interaction
with various transcription factors [50]. Furthermore, Tax
induces genome instability by deregulation of cell cycle
checkpoints. According to the chromosomal alterations
observed in ATL patients, it has been described that Tax
is able of inducing a delay in the cellular recognition and
response to DNA damage, and of suppressing the DNA
repair machinery activation [51]. Thus, Tax drives
genome instability and cellular transformation by inter-
fering with cell cycle checkpoint pathways and DNA
repair mechanisms. Hence, Tax can be considered a viral
oncoprotein, since Tax alone transforms rat fibroblasts
and primary human T lymphocytes, while transgenic
mice expressing Tax develop tumors [52]. Moreover,
recent evidence supports a role for the HTLV-1 basic leu-
cine-zipper factor (HBZ) as an additional viral player in
cancer development [53,54]. Interestingly, HBZ expres-
sion in transgenic mice confers a phenotype similar to the
one observed in ATL patients, and in particular the infil-
tration of lymphocytes into skin and lung [53,54]. A sche-
matic representation of HBZ role in HTLV-1 mediated
oncogenesis is reported in Figure 1. Finally, it has been
shown that HTLV-1 is able of altering the major histo-
compatibility complex class-I (MHC-I) and the T cell
receptor (TCR) cascade activation through the accessory
protein p12. p12 targets the free MHC-I chain and
increases Signal Transducer and Activator of Transcrip-
tion-5 (STAT-5) protein activation and calcium release
[55]. Furthermore, p12 decreases viral expression in
TCR-stimulated T cells and is recruited to the immuno-
logical synapse [56]. Besides, HTLV-1 accessory proteins
p13II is able to target the mitochondria and to induce
changes in its morphology. In particular, the effects on
mitochondria result mainly at the membrane permeabil-
ity level, altering the inner membrane potential, and the
oxygen consumption (respiration), thus affecting cellular
proliferation, apoptosis, and reactive oxygen species
(ROS) production [57,58].
The hypothesis of an HIV-1 involvement in tumor
pathogenesis is based on the evidence that AIDS-related
tumors have been described, such as KS, non-Hodgkin's
lymphomas (NHLs), and invasive cervical carcinoma
(ICC) [59]. HIV-1 infection can play a direct and/or indi-
rect role in HIV-1-related tumorigenesis. Among the
HIV-1 proteins of particular importance with regard to a
possible role in the carcinogenesis is the accessory pro-
tein Tat [60]. In this context, it has been proposed that
the Tat-induced DNA repair deficiencies may play a sig-
nificant role in the development of AIDS-associated can-
cers [60]. In particular, in the case of ICC, HIV-1 Tat,
besides enhancing the activity of HPV oncogenes, by
upregulating HPV E6 and E7 gene expression [61], could
also promote cell cycle progression [61]. Moreover, it has
been suggested that Tat, by physically interacting with
pRb2/p130, might alter pRb2/p130 cell growth-suppres-
sive properties, leading to the loss of cell cycle control
[62].
Besides, considering clinical data about HIV-1-associ-
ated primary cerebral lymphoma, several important dif-
ferences of AIDS to non-AIDS related primary cerebral
lymphomas have been described [59,63,64]. Among them
are the higher aggressiveness, the presence of multi-focal
lesions, the reduced percentage of therapy responders,
and an elevated mortality [63,64].
In addition to the retroviruses, HCV, a member of the
Flaviviridae family, is associated with human cancer.
HCV infection affects more than 170 million individuals
worldwide and represents one of the main causes of
chronic liver disease (CLD) that can evolve in HCC [65].
Among patients infected with HCV, it is almost exclu-
sively those with cirrhosis (roughly 20%) who develop
HCC, revealing a major risk factor for malignant progres-
sion. For these patients, the annual risk for developing
HCC is 1% to 4%, with patients from Japan having an
even higher risk. Chronic inflammation and cirrhosis are
believed to play key roles in promoting HCV-associated
HCC, although the underlying mechanisms of this pro-
cess are not yet understood. In addition to HCC, HCV is
also involved in polyclonal B lymphocyte activation [66]
and epidemiological studies show that HCV seropositive
individuals have a 5.5 times higher risk developing NHL
compared to HCV-seronegative individuals [67]. Clonal B
cells may evolve to overt HCV-related NHL as result of
an antigen-driven process triggered by the E2 protein
[66,67]. Noteworthy, the characterization of clonal B cells
activation mechanisms may represent a suitable target to
develop a therapy for HCV-associated NHL [66,67].
Oncogenic DNA viruses: the discovery of tumor 
suppressors
By contrast to RNA viruses, usually oncogenes of DNA
tumor viruses lack any recognizable sequence similarities
to cellular genes and how the products of these viral
genes were able to transform cells was not elucidated till
late 1970s [68,69]. It has been demonstrated few years
earlier that SV40 was capable to induce tumor formation
in experimentally infected hamsters, by the expression of
the viral large tumor (T) antigen, the major oncogenic
determinant of SV40 [70-72]. By employing co-immuno-
precipitation techniques, it was shown that the SV40
large T antigen was interacting with a cellular protein
having an approximate molecular weight of 53 kDa.
Based on its size, this cellular protein was named p53.
This finding represented the first evidence that products
of DNA tumor virus oncogenes could function through
physical/direct interactions with cellular proteins. By
cloning p53 genes from neoplastic rodent and humanBergonzini et al. Infectious Agents and Cancer 2010, 5:11
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cells it was possible to demonstrate that in all cases the
coding sequences differed from those present in normal
cells, by carrying important gain-of-function mutations.
Indeed, p53 is mutated or lost in almost 50% of all human
cancer cases worldwide, representing the most com-
monly mutated gene in human tumors. This finding sug-
gests that p53 acts as a tumor suppressor gene, which in
contrast to proto-oncogenes function to prevent rather
than to promote cancer [73]. Several studies have con-
tributed to demonstrate that a wide variety of cellular
stress stimuli, such as DNA damage but also viral infec-
tion, induce the activation of p53, which binds to and reg-
ulates the activity of several important cellular factors
[73]. In this way, p53 controls cell cycle progression,
senescence, apoptosis, and DNA repair thus preventing
tumor formation by reducing the accumulation of genetic
lesions. In the case of viral infection p53 activation repre-
sents the attempt of the host cell to block viral replica-
tion, by inducing, for instance, apoptosis. Thus, several
DNA viruses have evolved proteins, such as the SV40
large T antigen, to bind and inactivate p53, in order to
escape the cellular antiviral response [45], with cell trans-
formation as a consequence.
Inactivation of p53 is not the only mechanisms evolved
by DNA oncogenic viruses which induces tumors. A sec-
ond tumor suppressor genes, was discovered by studying
the childhood tumor retinoblastoma (Rb) [74]. Rb sus-
ceptibility was linked to a single recessive trait and the
gene encoding the specific tumor suppressor gene was
identified and cloned [75,76] and the protein named Rb.
In 1988, Harlow, Livingston and co-workers, demon-
strated that the Rb protein immunoprecipitates with ade-
novirus E1A and with SV40 large T antigen from
transformed cells [77,78].
Studying the interactions among human adenovirus
E1A and SV40 large T antigen with Rb was essential for
understanding the cellular tumor suppressor function
[79] with the demonstration that a hypophosphorylated
form of Rb negatively regulates G1 to S phase progression
through the cell cycle by binding to and blocking the
activity of E2F, a transcriptional factor activating several
genes involved in cellular DNA replication. Cell progres-
sion through G1 to S phase depends on the G1 cyclin-
dependent kinases activity, which directly hyperphospho-
rylate and inactivate Rb leading to the release of active E2.
Viral oncoproteins specifically bind to and inactivate the
h y p o p h o s p h o ry l a t e d  f o r m  o f  R b .  T h u s  f r e e  a c t i v e  E 2 F
accumulates, with consequent uncontrolled cellular pro-
liferation.
In summary, studies of DNA tumor viruses provided
seminal contributions to our understanding of both Rb
and p53, two of the most important cellular tumor sup-
pressor proteins. Moreover, a common theme for DNA
tumor viruses emerged since it has been demonstrated
that oncoproteins encoded by SV40, adenovirus, and
HPV share similar capacities for inactivating both the Rb
and p53 tumor suppressors [45]. A schematic representa-
tion of DNA viruses and related cellular/viral genes
involved in oncogenesis is reported in Figure 2.
To date, the DNA viruses consistently associated with
human tumors, are the HBV, HPV, EBV, and HHV-8
[80,81]. In addition, several evidence suggest a causative
role in some human cancers also for SV40, BK Virus
(BKV) and JC Virus (JCV) [80-83].
HPV represents a typical example of human oncogenic
DNA virus. Specific genotypes have been clearly linked to
different forms of tumors, mainly cervical cancer, but also
some penile and upper aerodigestive tract carcinomas
[45,84]. Being the viral aetiology of the above tumors so
well established, as for HBV, it is expected that the
recently tested HPV vaccines [45,84] will have a profound
impact on their prevention [45,84-90]. The HPV E6 and
E7 oncoproteins play an important role in cervical
tumors development, and are continuously expressed in
the lesions, while tumor arises only several years after the
initial cellular immortalising events. In fact, the continu-
ous expression of E6 and E7 is required for maintenance
of the transformed phenotype, and prevention of cell
growth arrest and/or apoptosis [91,92]. The best-charac-
terised HPV16 E6 activity is its ability to induce degrada-
tion of the tumour suppressor protein p53 via the
ubiquitin pathway [93]. Moreover, among additional
functions, E6 protein can also interfere with cellular dif-
ferentiation and cell cycle progression [94]. E7 is an acidic
phosphoprotein of 98 amino acids, which is structurally
and functionally related to a gene product of other DNA
tumour viruses, the adenovirus E1A protein and SV40
large T antigen. As mentioned above, all three proteins
are capable of binding to the tumour suppressor protein
retinoblastoma (pRb1) and its related proteins p107 and
p130, involved in cell cycle regulation. By doing so, and
thanks to other functions, E7 controls cell cycle progres-
sion [94]. In addition to E6 and E7, HPV E5 protein, a
small hydrophobic protein, localized in the endomem-
brane compartments of the Golgi apparatus and endo-
plasmic reticulum could play a role in HPV
carcinogenesis. Indeed it has been demonstrated that
HPV E5 down-regulates surface MHC-I, thus preventing
its transport to the cell surface; hence, E5 can potentially
allow infected cells to escape adaptive immune response
of cytotoxic T lymphocytes (CTL), thus favouring viral
persistence [95,96].
As for HCV, HBV chronic infection represents an
important risk factor for the development of HCC, a
malignant tumor frequently observed in some countries
of Asia and Africa [97,98]. It is important to underlineBergonzini et al. Infectious Agents and Cancer 2010, 5:11
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how major achievements in the prevention of virus-
induced cancers may be attributable to strategies to con-
trol infection in human populations. In fact, HBV vacci-
nation has dramatically decreased the number of HCC
[45,99-101]. However, the molecular mechanisms of HBV
carcinogenesis are still not fully clarified. Different stud-
ies suggest a role for the hepatitis B virus × antigen
(HB×Ag) in this context. Indeed, in addition to a physical
binding and functional inactivation of p53, HB×Ag pro-
motes fibrogenesis by stimulating fibronectin expression,
inhibits apoptosis mediated by Fas and tumor necrosis
factor-alpha (TNF-α) and its expression correlates with
the development and progression of CLD [102,103]. In
particular, HB×Ag expressed by HBV genome integrated
into chromosomal DNA is often functional in trans-acti-
vation assays [102]. Moreover, it can alter patterns of host
gene expression, contributing to carcinogenesis, by acti-
vating signal transduction pathways in host-infected cells
[102,103]. HB×Ag transforms cell lines in vitro, giving
rise to liver cancer in transgenic mice [103]. A role in the
ability of HB×Ag to modulate specific cell pathways has
been linked to the upregulated gene clone 11 (URG11)
cellular protein, which appears to be a direct effector of
the viral protein. Indeed, URG11 is upregulated in
HB×Ag-positive liver cells and seems to be involved in
cancer evolution, by controlling cell cycle progression
[103].
There is emerging interest in the polyomaviruses as
possible human carcinogens [80,83,104-107]. SV40,
which naturally infects the rhesus monkey, was inadver-
tently introduced into the human population as a con-
taminant of early poliovirus vaccines, whereas the BK and
JC polyomaviruses are natural human pathogens associ-
ated with disease processes in the urinary tract or brain,
respectively. Genomic sequences of these three polyoma-
viruses, which are tumorigenic under experimental con-
ditions, have been detected in human mesothelioma,
osteosarcoma, NHL, brain tumors, and prostate cancer.
In addition, an integrated form of a new polyomavirus,
MCPyV, was recently observed in Merkel cell carcinoma,
Figure 2 (A) Representative* list of cellular/viral protein interactions involved in DNA virus-related oncogenic transformation; (B) p53 and 
Rb are central targets of viral oncoproteins. The viral proteins Large T antigen of SV40, E1A/E1B of Adenovirus, and E6/E7 of HPV, are capable of 
interfering with either Rb and/or p53, altering their activities and thus essential cell cycle check-points. PP2A: Protein Phosphatase 2A; TRAFs:Tumor 
necrosis Factor Associated. * Additional cellular/viral interactions involved in cell transformation and oncogenetic mechanisms have been described.
EBV
SV40
Virus Viral  oncoprotein Cellular  targets
Adenovirus
HPV
Large T antigen
Small t antigen
E1A
E1B
E6
E7
LMP1
p53, Rb
PP2A
Rb
p53
Rb
p53
TRAFs, NF-κB
A)
B)
HBV X protein p53Bergonzini et al. Infectious Agents and Cancer 2010, 5:11
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a rare but aggressive human skin cancer of neuroendo-
crine origin [39,84].
EBV and HHV-8 are two members of the Herpesviridae
family that are classified as cancerogenic agents. These
viruses can establish long-term viral infections in their
target cells, promoting cellular immortalisation and
transformation [80,81]. EBV is the most important aetio-
logical factor in classic BL [108], and it is also detectable
in undifferentiated nasopharyngeal carcinomas, in a sub-
set of HL, and in some cases of NHL, notably in immuno-
suppressed patients [79,80,108].
The alteration of cell signaling represents the molecular
basis for cellular proliferation occurring in association
with several viral infections. In particular, both EBV and
HHV-8 target important cell signaling pathways involved
in oncogenesis, such as the β-catenin pathway that plays a
key role in the control of cell adhesion and tissue mor-
phogenesis [109,110]. The level of β-catenin protein is
subject to tight regulation, particularly through ubiq-
uitin-mediated proteasomal degradation. Latent mem-
brane protein-1 (LMP-1) and latent membrane protein-
2A (LMP-2A) of EBV affect the β-catenin stabilization
and activation avoiding the ubiquitination [110], as many
other oncoproteins of tumorigenic viruses, such as T
antigen in JCV [105]. It is beginning to emerge that tumor
viruses modulate the ubiquitination of specific cell fac-
tors for their needs [111,112] by employing different
strategies. Among them, viruses encode their own ubiq-
uitin ligases and deubiquitinating enzymes (DUBs), as
recently demonstrated in the case of herpesviruses
[112,113]. Indeed, since the discovery that the largest teg-
ument protein of Human Herpes Virus-1 (HSV-1), UL36,
contains a deubiquitinating activity it has been reported
that all members of the Herpesviridae family, including
EBV and HHV-8, encode UL36 homologues, suggesting
an important role of this protein in the viral life cycle
[111,114]. On the other hand, the presence of the viral
latency-associated nuclear antigen (LANA) in all HHV-8-
associated tumors significantly correlates with β-catenin
over-expression. In this context it has been demonstrated
that introduction of anti-LANA small interfering RNA
(siRNA) into primary effusion lymphomas (PEL) cells
eliminated β-catenin accumulation, while LANA itself
upregulated expression of β-catenin in transfected cells.
LANA stabilizes β-catenin by binding to its negative reg-
ulator GSK-3β, causing a cell cycle-dependent nuclear
accumulation of GSK-3β [115]. The importance of this
pathway to HHV-8-driven cell proliferation is highlighted
by the observation that LANA stimulates entry into S
phase.
In the past 10 years much effort has been devoted to the
study of HHV-8. HHV-8 is consistently detected in all
forms of KS, in PEL, and in a subset of multicentric Cas-
tleman's disease [116,117]. During the latency program of
γ-herpesvirus infection, few viral genes are expressed.
Whereas EBV latent proteins contribute to cell immortal-
ization, HHV-8 lytic genes play an important role in can-
cer development and progression. An Italian study
investigated the latent and lytic antibodies seropreva-
lence in elderly subjects, and the possible correlation with
clinical stage and disease progression in classical KS
[118,119]. While the antibody levels against HHV-8 latent
antigens were observed in all KS cases, antibody levels
against HHV-8 lytic antigens increase with the progres-
sion of KS, and higher HHV-8 antibody levels were
observed in the fast progressive form of the disease [119].
According to the literature, these results support the
hypothesis that active viral replication probably contrib-
utes to progression of KS. In addition, HHV-8 DNA was
constantly detected in saliva and PBMC samples of classi-
cal KS but without any correlation with the clinical stage
of the disease, suggesting that oral shedding is likely to
occur in these patients and contributes to viral transmis-
sion [119].
Conclusive remarks
By the first decade of the 21st Century, much evidence
had accumulated pointing out at least six human viruses,
namely HPV, HBV, EBV, HHV-8, HCV, and HTLV-1, as
aetiologic agents of human cancers. As mentioned above
these viruses are responsible of roughly 20% of all human
tumors worldwide [45]. Moreover, oncogenic viruses
have also proved to be powerful tools for dissecting fun-
d a m e n t a l  p a t h w a y s  a n d  p r o t e i n s  i n v o l v e d  i n  c e l l  c y c l e
progression and regulation. For example, a number of
oncogenes have been identified through studies focused
on RNA tumor viruses, while essential tumor suppres-
sors, such as p53 and Rb, were discovered and character-
ized through DNA tumor viruses. In the future, it is
expected that the characterization of new tumor viruses
will contribute in clarifying relevant aspects of cell biol-
ogy and carcinogenesis. Indeed, other candidate human
tumor viruses have been proposed [120]. Particularly
intriguing in this context is the study of human endoge-
n o u s  r e t r o v i r u s e s  r o l e  i n  s e m i n o m a s ,  b r e a s t  c a n c e r ,
myeloproliferative disease, ovarian cancer, melanoma,
and prostate cancer [121]. Moreover, as demonstrated in
the case of HBV and HPV, prophylactic vaccines offer the
potential to prevent cancers having a viral aetiology.
Thus, the development of new vaccines against other
human tumor viruses should be a must for the future
research.
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